Page last updated: 2024-11-04

erythrosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Erythrosine is a synthetic xanthene dye with the chemical formula C20H6I4Na2O5. It is a red-colored dye that is used as a food coloring, in cosmetics, and in pharmaceuticals. Erythrosine is synthesized from fluorescein by iodination. It is a potent photosensitizer, meaning it absorbs light and transfers energy to other molecules, which can lead to oxidative damage. Erythrosine has been studied for its potential use in photodynamic therapy, a treatment for cancer that involves the use of light and a photosensitizer to destroy cancer cells. Erythrosine is also being investigated for its potential use in other applications, such as antimicrobial agents, fluorescent probes, and bioimaging agents.'

Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Erythrosine: A tetraiodofluorescein used as a red coloring in some foods (cherries, fish), as a disclosure of DENTAL PLAQUE, and as a stain of some cell types. It has structural similarity to THYROXINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

erythrosin B : An organic sodium salt that is the disodium salt of 2-(2,4,5,7-tetraiodo-6-oxido-3-oxo-8a,10a-dihydroxanthen-9-yl)benzoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3259
CHEMBL ID1332616
SCHEMBL ID25042
MeSH IDM0007727
PubMed CID12961638
CHEMBL ID2106219
SCHEMBL ID19080
MeSH IDM0007727

Synonyms (183)

Synonym
2,5,7-erythrosin
fluorescein,4',5',7'-tetraiodo-
iodeosin
nsc-328781
15905-32-5
2',5',7'-tetraiodofluorescein
spiro[isobenzofuran-1(3h), 3',6'-dihydroxy-2',4',5',7'-tetraiodo-
2,5,7-tetraiodofluorescein
nsc328781
erythrosine acid
nsc 328781
brn 0062817
erythrosine, phenolic
fluorescein, 2',4',5',7'-tetraiodo- (van)
2',4',5',7'-tetraiodofluorescein
einecs 240-046-0
tetraiodofluorescein
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 3',6'-dihydroxy-2',4',5',7'-tetraiodo-
2,4,5,7-erythrosin
3',6'-dihydroxy-2',4',5',7'-tetraiodospiro(isobenzofuran-1(3h),9'-(9h)xanthene)-3-one
SMP2_000049
NCGC00166249-01
erythrosin b, dye content >=95 %
MLS001332406
MLS001332405
smr000857151
c.i. 45430:2
solvent red 140
T0124
iodoeosine
3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one
NCGC00166249-02
unii-1a878fzq9b
4-19-00-02923 (beilstein handbook reference)
fluoresceins
1a878fzq9b ,
cas-15905-32-5
c.i. solvent red 140
NCGC00256240-01
tox21_301634
dtxcid1024207
dtxsid7044843 ,
tox21_113464
CHEMBL1332616
e127
AKOS015903873
erythrosine j
ci 45430:2
3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro(2-benzofuran-1,9'-xanthen)-3-one
SCHEMBL25042
tox21_113464_1
NCGC00166249-03
tetrajodfluorescein
OALHHIHQOFIMEF-UHFFFAOYSA-N
tetra-iodo-fluorescein
c20h8i4o5
spiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one, 3',6'-dihydroxy-2',4',5',7'-tetraiodo-
HB0759
solvent red 140; tetraiodofluoresceuin; erythrosine
STL453505
3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthen]-3-one
AS-74205
J-009558
trace
cogilor orange 211.10
pyrosine b
red 1427
2, 4,5,7-tetraiodofluorescein
dianthine b
felumin
3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[isobenzofuran-1(3h),9'(9h)-xanthen]-3-one, 9ci
iodeosine b
ceplac
cogilor orange 312.42
Q420101
e127 erythrosine
spiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one,3',6'-dihydroxy-2',4',5',7'-tetraiodo-
3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one
tetraiodofluoresceuin
bdbm50542241
CS-0030748
erythrosine sodium (close form)
16423-68-0
9-(o-carboxyphenyl)-6-hydroxy-2,4,5,7-tetraiodo-3h-xanthene-3-one disodium salt monohydrate
erythrosine tb
fd and c red no. 3
usacert red no. 3
erythrosine extra
cerven kysela 51 [czech]
hexacol erythrosine bs
erythrosine extra bluish
erythrosine b (biological stain)
cerven potravinarska 14 [czech]
fd and c red 3
erythrosine sodium (close form) [usan]
3',6'-dihydroxy-2',4',5',7'-tetraiodospiro(isobenzofuran-1(3h),9'- -(9h)xanthen)-3-one, disodium salt
erythrosine bluish
new pink bluish geigy
erythrosine tb extra
erythrosin b
einecs 240-474-8
erythrosine bs
food red no. 3
erythrosine i
erythrosine (indicator)
erythrosine bluish (biological stain)
hexacert red no. 3
edicol supra erythrosin as
caswell no. 425ab
erythrosine extra conc. a export
food dye red 3
erythrosine b-fo (biological stain)
ccris 892
erythrosine extra pure a
c.i. food red 14
erythrosine lake
epa pesticide chemical code 120901
e 127
sodium erythrosin
edicol supra erythrosine a
erythrosine b
maple erythrosine
red dye no. 3
erythrosine k-fo (biological stain)
ai3-09094
dolkwal erythrosine
dye fd and c red no. 3
fdc red 3 dye
disodium 2',4',5',7'-tetraiodofluorescein
lb-rot 1
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 3',6'-dihydroxy-2',4',5',7'-tetraiodo-, disodium salt
schultz no. 887
fdc red 3
d&c red no. 3
cilefa pink b
erythrosine 3b
erythrosine
disodium 3',6'-dihydroxy-2',4',5',7'-tetraiodospiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one
2',4',5',7'-tetraiodofluorescein, disodium salt
c.i. acid red 51
disodium 9-(o-carboxyphenyl)-6-hydroxy-2,4,5,7-tetraiodo-3h-xanthen-3-one monohydrate
canacert erythrosine bs
calcocid erythrosine n
erythrosin extra bluish, certified by the biological stain commission
erythrosin b, certified by the biological stain commission, dye content 90 %
2-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate
nsc 759227
erythrosine sodium (open form)
cerven kysela 51
benzoic acid, 2-(6-hydroxy-2,4,5,7-tetraiodo-3-oxo-3h-xanthen-j9-yl)-, disodium salt
unii-8tl7lh93fm
erythrosine sodium (open form) [usan]
cerven potravinarska 14
nsc 36685
benzoic acid, 2-(6-hydroxy-2,4,5,7-tetraiodo-3-oxo-3h-xanthen-9-yl)-, disodium salt
hsdb 7974
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 3',6'-dihydroxy-2',4',5',7'-tetraiodo-, sodium salt (1:2)
fluorescein, 2',4',5',7'-tetraiodo-, disodium salt (benzoic acid tautomeric form)
NCGC00255371-01
tox21_302085
cas-16423-68-0
dtxcid301030411
dtxsid7021233 ,
fd&c red 3
tox21_202932
NCGC00260478-01
CHEMBL2106219
AKOS016010498
FT-0625707
AKOS015904033
SCHEMBL19080
sodium 2',4',5',7'-tetraiodo-3-oxo-3h-spiro[isobenzofuran-1,9'-xanthene]-3',6'-bis(olate)
mfcd00144257
erythrosin extra bluish
erythrosin b, analytical standard
erythrosin extra bluish, for microscopy (bact., hist.), adsorption and fluorescent indicator
erythrosin extra bluish, 87.0-100.0%
erythrosin b disodium
erythrosin b disodium 100 microg/ml in acetonitrile/water
disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate
sodium 2',4',5',7'-tetraiodo-3-oxo-3h-spiro-[isobenzofuran-1,9'-xanthene]-3',6'-bis(olate)
bdbm50523756
eritrosina

Research Excerpts

Actions

ExcerptReferenceRelevance
"An erythrosine dose-related increase in the mitotic frequency was due to an increase in the number of first mitoses at the expense of later cell divisions."( A multiple end-point approach to evaluation of cytotoxicity and genotoxicity of erythrosine (FD and C Red No. 3) in a V79 hepatocyte-mediated mutation assay.
Boyes, BG; Clayson, DB; Héroux-Metcalf, C; Matula, TI; Rogers, CG,
)
0.87

Toxicity

There were no adverse effects of erythrosine on either litter size, litter weight or sex ratio at birth.

ExcerptReferenceRelevance
" Using sulfamethoxazole hydroxylamine (SMX-HA) as a model compound, we report the use of a pH-sensitive fluorescent probe, 2',7'-biscarboxyethyl-5(6)-carboxyfluorescein (BCECF), to identify early subcellular targets of chemically synthesized, toxic drug metabolites in peripheral blood mononuclear cells."( Cellular toxicity of sulfamethoxazole reactive metabolites--I. Inhibition of intracellular esterase activity prior to cell death.
Dosch, HM; Leeder, JS; Spielberg, SP, 1991
)
0.28
" There was no apparent relationship between drug reversal of vcr resistance and the cytotoxic actions of the drug per se since the calcium channel blocker diltiazem (dil) significantly potentiated the actions of vcr on MDR L100 cells without being more toxic to these cells (compared to vcr-sensitive L0 cells)."( Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.
Larsson, R; Nygren, P, 1990
)
0.28
"Injection of fluorescein intravenously for fundal angiography is associated with a high incidence of minor adverse effects (21%) but a very low incidence of serious (life threatening) reactions (0."( Oral fluorescein angiography: reassessment of its relative safety and evaluation of optimum conditions with use of capsules.
Rosen, ES; Watson, AP, 1990
)
0.28
"The penetration of sulforhodamine B (SRB) into the two corneas of a freshly killed mouse was measured after one eye was briefly exposed to a solution of a possibly toxic substance."( A permeability test for acute corneal toxicity.
Maurice, D; Singh, T, 1986
)
0.27
"A drug registry was established at Southern California College of Optometry (SCCO) to study use rates and incidence of adverse side effects of the nine pharmaceutical agents in the California optometry law."( Use of diagnostic pharmaceutical agents and incidence of adverse effects.
Applebaum, M; Jaanus, SD, 1983
)
0.27
" Dihydroergocryptine antagonized both the neuronal death produced by acute exposure to a toxic glutamate concentration as well as the normal age-dependent degeneration in culture."( Protection by dihydroergocryptine of glutamate-induced neurotoxicity.
Aleppo, G; Canonico, PL; Favit, A; Scapagnini, U; Sortino, MA, 1993
)
0.29
" The BCECF proliferative assay is fast (the results are obtained within 3-4 days depending on the cell line), accurate, not labor-intensive, does not require the use of radioisotopes or toxic compounds, and is amenable to automation."( A cytotoxicity assay utilizing a fluorescent dye that determines accurate surviving fractions of cells.
Cook, S; Goldmacher, VS; Sellers, JR, 1994
)
0.29
" Hepa 1c1c-9 cells were exposed to varying concentrations of several reactive metabolites implicated in adverse drug reactions and the toxicity of the compounds assessed using applied fluorescence technology."( A comparative study of the toxicity of chemically reactive xenobiotics towards adherent cell cultures: selective attenuation of menadione toxicity by buthionine sulphoximine pretreatment.
Leeder, JS; Riley, RJ; Spielberg, SP, 1993
)
0.29
" Weak acids that are normal cellular metabolites are not toxic in vivo, but weak acids carrying cytotoxic groups offer the potential for selective uptake and toxicity under the conditions of low pHe that exist in many solid tumours."( Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment.
Dobrowsky, E; Karuri, AR; Tannock, IF, 1993
)
0.29
" Therefore, the purpose of this study was to address whether CsA is directly toxic to renal parenchymal cells in a primary culture system of rat renal cortical epithelial cells."( An in vitro model of cyclosporine-induced nephrotoxicity.
Acosta, D; Jiang, T, 1993
)
0.29
" However, both the method of intracellular loading--which for many fluorophores involves endogenous esterase-mediated removal of hydrophobic groups such as acetoxymethyl esters (AM)--and fluorescence excitation of fluorophores in the cell, can produce toxic metabolites and reactive species."( Fluorophore toxicity in mouse eggs and zygotes.
Baltz, JM; Phillips, KP; Zhou, WL, 1998
)
0.3
" Carvedilol and verapamil (10 micromol/L) reduced the LD50 (dose which results in the death of half the number of cells) of the Hs578T-Dox subline from 200 mg/L to approx."( Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Jonsson, O; Persson, M, 1999
)
0.3
" A laboratory study was performed in a defined test model to compare the toxicity of natural and pharmaceutical tear substitutes and to identify potentially toxic factors in natural tear substitutes, such as amylase, hypotonicity, and variations in preparation."( Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells.
Cree, IA; Daniels, JT; Dart, JK; Geerling, G; Khaw, PT, 2001
)
0.31
" Preserved hypromellose was more toxic than the unpreserved preparation."( Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells.
Cree, IA; Daniels, JT; Dart, JK; Geerling, G; Khaw, PT, 2001
)
0.31
"To investigate whether the toxic effect on cultured retinal pigment epithelial (RPE) cells after application of indocyanine green is related to the osmolarity of the solvent or to toxic effects of the dye and evaluate whether these changes also occur using infracyanine green."( Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent.
Feron, EJ; Stalmans, I; Stalmans, P; Van Aken, EH; Veckeneer, M, 2002
)
0.31
" Rat Abeta(1-42) combined with iron was as toxic as iron alone, whereas iron combined with human Abeta(1-42) was significantly less toxic."( Human Abeta1-42 reduces iron-induced toxicity in rat cerebral cortex.
Bishop, GM; Robinson, SR, 2003
)
0.32
" Trypan blue is safe in a cell culture model."( Safety testing of indocyanine green and trypan blue using retinal pigment epithelium and glial cell cultures.
Hillenkamp, J; Jackson, TL; Knight, BC; Marshall, J; Stanford, MR; Thomas, D; Zhang, JJ, 2004
)
0.32
" These findings confirm a key role for glutathione in protecting cells from CsA-induced adverse effects and do not support a direct link between CsA-mediated ROS generation and adverse renal effects."( Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells.
Capasso, G; Chiodini, P; Della Ragione, F; Di Gennaro, CI; Galletti, P; Indaco, S; Manna, C; Migliardi, V; Zappia, V, 2005
)
0.33
"The genotoxicity of benzoquinone (BQ), a toxic benzene metabolite, is greatly enhanced by the presence of fetal calf serum (FCS) in the incubation medium."( Involvement of oxygen free radicals in the serum-mediated increase of benzoquinone genotoxicity.
De Bartolomeo, A; Fabiani, R; Morozzi, G, 2005
)
0.33
" A modified 'amyloid cascade' hypothesis for Alzheimer's disease states that prefibrillar oligomers, also called amyloid-beta-derived diffusible ligands or globular oligomers, are the responsible toxic agent."( Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity.
Anderluh, G; Ceru, S; Gutierrez-Aguirre, I; Kopitar-Jerala, N; Macek, P; Rabzelj, S; Turk, V; Zerovnik, E, 2005
)
0.33
" The addition of homocysteinic acid in a nontoxic concentration of 100 microM potentiated the toxic effect of NMDA and led to massive cell death."( Homocysteinic acid causes oxidative stress in lymphocytes by potentiating toxic effect of NMDA.
Boldyrev, AA, 2005
)
0.33
" In conclusion, the present data suggest that both antioxidant systems, glutathione and trypanothione/trypanothione reductase, participate in protection of Leishmania against the toxic effect of nitrogen-derived reactive species."( Glutathione and the redox control system trypanothione/trypanothione reductase are involved in the protection of Leishmania spp. against nitrosothiol-induced cytotoxicity.
Cruz, AK; Cunha, FQ; Ferreira, SH; Fonseca, SG; Hothersall, JS; Moraes, RH; Noronha-Dutra, AA; Romão, PR; Tovar, J, 2006
)
0.33
" Considering that the oxidation of DCFH diminishes ROS generated by various stressors, our findings provide a potential strategy for protection of cells from toxic insults using DCFH-like molecules."( The antioxidant role of a reagent, 2',7'-dichlorodihydrofluorescin diacetate, detecting reactive-oxygen species and blocking the induction of heme oxygenase-1 and preventing cytotoxicity.
Adachi, Y; Andoh, Y; Ikehara, S; Ishii, T; Kojo, S; Mizutani, A; Ohashi, T; Taketani, S, 2006
)
0.33
" From the viewpoint of developing effective and safe protein transduction technology, although Tat was the most versatile carrier among the peptides studied, PTDs should be selected based on their individual characteristics."( Comparative study on transduction and toxicity of protein transduction domains.
Imai, S; Kamada, H; Mukai, Y; Nagano, K; Nakagawa, S; Shibata, H; Sugita, T; Tsunoda, SI; Tsutsumi, Y; Yamanada, N; Yoshida, Y; Yoshikawa, T; Yoshioka, Y, 2008
)
0.35
" Therefore, we compared in these two cell types the toxic effects of the preservative, benzalkonium chloride (BAC); its toxicity has been often reported on conjunctival in vivo and in vitro models."( Comparative study on the cytotoxic effects of benzalkonium chloride on the Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines.
Baudouin, C; Brasnu, E; Brignole-Baudouin, F; Riancho, L; Warnet, JM, 2008
)
0.35
" This study provides likely explanations for clinically observed adverse liver effects of CP-724,714."( Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Bi, YA; Campbell, S; Davidson, R; Duignan, DB; Dunn, MC; Feng, B; Kostrubsky, VE; Mireles, R; Smith, AR; Wang, HF; Xu, JJ, 2009
)
0.35
" These findings suggest that the solubilizing agents at these concentrations except for NaTC, Gelucire 44/14 and Cremophor EL are considered safe and do not cause intestinal membrane damage."( The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats.
Hamid, KA; Katsumi, H; Sakane, T; Yamamoto, A, 2009
)
0.35
"This study evaluates the toxic effects of catechol (a component from cigarette smoke) on Müller cells (MIO-M1) in vitro, and investigates the inhibitors memantine and epicatechin to determine if they can reverse the catechol toxic effects."( Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro.
Gupta, N; Kenney, MC; Kuppermann, BD; Limb, GA; Luczy-Bachman, G; Mansoor, S, 2010
)
0.36
"Only long-chain (>C14) saturated NEFAs were toxic to insulin-producing cells."( Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells.
Elsner, M; Gehrmann, W; Lenzen, S, 2011
)
0.37
" Furthermore, effects on mitochondrial network, focal adhesions, actin cytoskeleton and caspase-3 activation were analyzed and adverse effects were evident at 20 μM peptide concentration within 4 h while parent L-peptides had negligible effects."( Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity.
Andaloussi, SE; Hein, M; Holm, T; Langel, Ü; Mäe, M; Pooga, M; Räägel, H, 2011
)
0.37
" Although various surface modifications are being done for making these nonbiodegradable nanoparticles more biocompatible, their toxic potential is still a major concern."( Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress.
Abdin, M; Ahmed, FJ; Dinda, AK; Maitra, A; Naqvi, S; Prashant, C; Samim, M, 2010
)
0.36
" Methanol and ethanol were the least toxic cryoprotectants tested."( Studies on cryoprotectant toxicity to zebrafish (Danio rerio) ovarian tissue fragments.
Anil, S; Ghafari, F; Rawson, DM; Zampolla, T; Zhang, T,
)
0.13
" Results of the present work exclude peroxynitrite involvement in cytokine toxicity to β-cells because its generation did not correlate with the toxic action of cytokines."( Cytokine toxicity in insulin-producing cells is mediated by nitro-oxidative stress-induced hydroxyl radical formation in mitochondria.
Gurgul-Convey, E; Lenzen, S; Lortz, S; Mehmeti, I, 2011
)
0.37
" Therefore, Aβ42 DNA trimer immunization has a high probability to be effective and safe to treat patients with early AD."( DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.
Anderson, LD; Eagar, TN; Fu, M; Lambracht-Washington, D; Qu, BX; Rosenberg, RN; Stüve, O, 2011
)
0.37
" It is necessary to seek strategies that avoid the possible adverse effects after anaesthesia."( Clonidine abolishes the adverse effects on apoptosis and behaviour after neonatal ketamine exposure in mice.
Eriksson, P; Fredriksson, A; Gordh, T; Pontén, E; Viberg, H, 2012
)
0.38
"The administration of clonidine eliminated the adverse effects of ketamine in this mouse model, suggesting a possible strategy for protection."( Clonidine abolishes the adverse effects on apoptosis and behaviour after neonatal ketamine exposure in mice.
Eriksson, P; Fredriksson, A; Gordh, T; Pontén, E; Viberg, H, 2012
)
0.38
"001% BAC) was the least toxic in our experimental conditions."( Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets.
Aihara, M; Amano, S; Araie, M; Kimakura, M; Miyata, K; Mori, Y; Nakagawa, S; Omichi, S; Usui, T; Yokoo, S, 2012
)
0.38
"001% or lower or non-BAC preservative sofZia was suggested to be the least toxic to the ocular surface."( Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets.
Aihara, M; Amano, S; Araie, M; Kimakura, M; Miyata, K; Mori, Y; Nakagawa, S; Omichi, S; Usui, T; Yokoo, S, 2012
)
0.38
" The results show that bismuth nanoparticles are more toxic than most previously reported bismuth compounds."( In vitro cytotoxicity of surface modified bismuth nanoparticles.
Hossain, M; Luo, Y; Ma, L; Qiao, Y; Su, M; Wang, C, 2012
)
0.38
" Based on the results, the four essential oils are considered safe for human consumption at low concentrations."( Evaluation of toxicity of essential oils palmarosa, citronella, lemongrass and vetiver in human lymphocytes.
Ghosh, M; Jothiramajayam, M; Mukherjee, A; Sinha, S, 2014
)
0.4
" Adverse retinal staining was not noted and the final visual acuity showed no difference with multiple staining."( Brilliant Blue G double staining enhances successful internal limiting membrane peeling with minimal adverse effect by low cellular permeability into live cells.
Asato, R; Enaida, H; Hisatomi, T; Ikeda, Y; Ishibashi, T; Murakami, Y; Notomi, S; Oishi, S; Sakamoto, T; Tachibana, T; Yamashita, T, 2015
)
0.42
" ATZ has been associated with adverse effects on the immune system; however, the mechanism of its immunotoxicity has not been completely elucidated."( Effects of atrazine on the proliferation and cytotoxicity of murine lymphocytes with the use of carboxyfluorescein succinimidyl ester-based flow cytometric approaches.
Chen, J; Huo, J; Jia, Z; Li, Y; Song, Y; Zhang, L, 2015
)
0.42
" The results suggest that biochar may have an excellent ability to mitigate the toxic effects of Pb(II) on soil microorganisms and rice."( Biochar amendment to lead-contaminated soil: Effects on fluorescein diacetate hydrolytic activity and phytotoxicity to rice.
Gu, Y; Guo, Y; Hu, X; Liu, Y; Sun, Z; Tan, X; Wang, X; Zeng, G; Zeng, X, 2015
)
0.42
" Our data shows that the addition of rPrP to the assembling Aβ42 results in a shift in oligomer size distribution, decreasing the population of toxic tetramers and higher order oligomers and increasing the population of nontoxic (and possibly neuroprotective) monomers."( Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition.
Choi, JK; Surewicz, K; Surewicz, WK; Williams, TL, 2015
)
0.42
" It is one of the most toxic compounds belonging to organochlorines."( The Crucial Involvement of Retinoid X Receptors in DDE Neurotoxicity.
Kajta, M; Krzeptowski, W; Lasoń, W; Litwa, E; Rzemieniec, J; Wnuk, A; Wójtowicz, AK, 2016
)
0.43
" Additionally, adverse effects of MWCNTs at low concentration are not well understood."( Comparison of Cytotoxicity and Inhibition of Membrane ABC Transporters Induced by MWCNTs with Different Length and Functional Groups.
Cherr, GN; Li, M; Liu, S; Shen, Z; Wu, B; Yu, J; Zhang, XX, 2016
)
0.43
" Pituitary adenylate cyclase-activating polypeptide (PACAP) is an endogenous 38 amino-acid peptide with demonstrated protection against neuronal injury, trauma as well as various endogenous and exogenous toxic agents."( PACAP Protects Against Ethanol and Nicotine Toxicity in SH-SY5Y Cells: Implications for Drinking-Smoking Co-morbidity.
Csoka, AB; Getachew, B; Khundmiri, SJ; Manavalan, S; Manaye, KF; McKinley, R; Reglodi, D; Tamas, A; Tizabi, Y, 2017
)
0.46
" In conclusion, a hepatocyte specific drug delivery system was designed, which is safe and biocompatible and which can be used to implement liver-specific targeting strategies."( PDMS-b-PMOXA polymersomes for hepatocyte targeting and assessment of toxicity.
Ernst, A; Grossen, P; Huwyler, J; Kiene, K; Porta, F; Schenk, SH; Witzigmann, D, 2017
)
0.46
"Conventional in vitro assays are often used as initial screens to identify potential toxic effects of nanoparticles (NPs)."( An Alternative In Vitro Method for Examining Nanoparticle-Induced Cytotoxicity.
Ali, SF; Cuevas, E; Gu, Q; Jones, Y; Krauthamer, V; Paule, MG; Zhang, Y,
)
0.13
"The CLS shows a great potential for a safe and tolerable 24-hr IOP monitoring in normal subjects and glaucoma patients."( A New Contact Lens Sensor System for Continuous Intraocular Pressure Monitoring: Evaluation of Safety and Tolerability.
Chen, Z; Chong, IT; Deng, M; Karunaratne, IK; Lam, DCC; Lee, CHC; Wei, Y; Yang, Y; Yu, M; Zhang, Y, 2022
)
0.72
" The potential adverse effects of erythrosine (ER, FD & C Red No."( A study on the reproductive toxicity of erythrosine in male mice.
Abdel Aziz, AH; Attia, AS; Saad, SF; Shouman, SA, 1997
)
0.3
" There were no adverse effects of erythrosine on either litter size, litter weight or sex ratio at birth."( Reproductive and neurobehavioural toxicity study of erythrosine administered to mice in the diet.
Tanaka, T, 2001
)
0.31
" All the toothbrushes tested in this investigation were found to be safe with no evidence of hard or soft tissue trauma."( A 3-month comparative investigation of the safety and efficacy of a new toothbrush: results from two independent clinical studies.
Galustians, HJ; Jacobs, DM; King, DW; Low, MA; Qaqish, JG; Sharma, NC; Weber, DA, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" For intravenously administered fluorescein mean Cmax was 10."( Studies on the pharmacokinetics of fluorescein and its dilaurate ester under the conditions of the fluorescein dilaurate test.
Barry, RE; Behrendt, WA, 1985
)
0.27
" The compound showed a pharmacokinetic pattern similar to that of heparin and the plasmatic levels were linearly correlated with anti-factor Xa activity and logarithmically with lipoprotein lipase activation."( Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: Pharmacokinetics in rats.
Barbanti, M; Cristofori, M; Mastacchi, R; Sarret, M, 1985
)
0.27
" The plasma pharmacokinetic data were found to follow a biexponential decay in time."( Plasma pharmacokinetics and interstitial diffusion of macromolecules in a capillary bed.
Jain, RK; Nugent, LJ, 1984
)
0.27
"This study was undertaken to compare the effect of glucose injection on the pharmacokinetic behavior of a soluble dye in normal and tumoral tissues."( Noninvasive fluorescent study in situ and in real time of glucose effects on the pharmacokinetic of calcein.
Bégu, S; Devoisselle, JM; Mordon, S, 2002
)
0.31
"85 mL/h), and a long elimination half-life (mean T(1/2;β) = 307 hours)."( Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery.
Ding, R; Fardanesh, M; Frei, E; Haefeli, WE; Kremer, P; Schrenk, HH, 2011
)
0.37
" Based on numerous reports implicating the role of the ATP-binding cassette drug transporter P-glycoprotein (P-gp) in ivermectin efflux in dogs, an in vivo study was conducted to determine whether ivermectin toxicity results from a pharmacokinetic interaction with spinosad."( Pharmacokinetic interaction of the antiparasitic agents ivermectin and spinosad in dogs.
Balogh, L; Dunn, ST; Hedges, L; Lai, Y; Locuson, CW; Mahabir, S; Sampson, KE, 2011
)
0.37
" The physicochemical and pharmacokinetic properties of NOSC-modified DTX liposomes (NDLs) were evaluated compared with the conventional DTX liposomes (DLs) and commercial dosage form of DTX, Taxotere(®)."( N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics.
Qu, G; Wu, X; Yin, L; Zhang, C, 2012
)
0.38
"Transporter gene knockout rats are practically advantageous over murine models for pharmacokinetic and excretion studies, but their phenotypic characterization is lacking."( Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Bao, JQ; Bedwell, DW; Higgins, JW; Zamek-Gliszczynski, MJ, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" A combination with fluorescence labeling (FITC-dextran uptake) of macrophage-like cells, allowed us to demonstrate 1) the complete, regular distribution of both cell populations along the entire small intestine, and 2) the constant, intimate associations between interstitial cells of Cajal and macrophage-like cells."( Selective double staining of interstitial cells of Cajal and macrophage-like cells in small intestine by an improved supravital methylene blue technique combined with FITC-dextran uptake.
Mikkelsen, HB; Thuneberg, L; Wittrup, IH, 1988
)
0.27
"Because modulation of P-glycoprotein (Pgp) through inhibition or induction can lead to drug-drug interactions by altering intestinal, central nervous system, renal, or biliary efflux, it is anticipated that information regarding the potential interaction of drug candidates with Pgp will be a future regulatory expectation."( In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Balakrishnan, A; Humphreys, JE; Keogh, JP; Kunta, JR; Polli, JW; Rautio, J; Serabjit-Singh, CJ; Webster, LO, 2006
)
0.33
" Importantly, using freshly isolated PBCECs in suspension in combination with fluorescence-activated cell sorting analysis reduced experimental time to 4hrs vs 7d with cultured PBCECs monolayers, while retaining and even improving feasibility, reliability, specificity, and sensitivity of the assay."( Rapid assessment of p-glycoprotein-drug interactions at the blood-brain barrier.
Bubik, M; Fricker, G; Mahringer, A; Ott, M, 2006
)
0.33
"The in vitro antimicrobial activities of pannarin, a depsidone isolated from lichens, collected in several Southern regions of Chile (including Antarctica), was evaluated alone and in combination with five therapeutically available antibiotics, using checkerboard microdilution assay against methicillin-resistant clinical isolates strains of Staphylococcus aureus."( In vitro antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant Staphylococcus aureus clinical isolates.
Amicosante, G; Bellio, P; Brisdelli, F; Celenza, G; Garbarino, JA; Nicoletti, M; Perilli, M; Piovano, M; Segatore, B; Setacci, D, 2012
)
0.38
"We previously reported a quantitative time-lapse imaging (QTLI)-based analysis method to assess drug-drug interactions (DDI) at multidrug resistance-associated protein 2 (Mrp2) in rat sandwich-cultured hepatocyte (SCH) system, utilizing the fluorescent Mrp2 substrate, 5-(and 6)-carboxy-2',7'-dichlorofluorescein (CDF)."( Application of quantitative time-lapse imaging (QTLI) for evaluation of Mrp2-based drug-drug interaction induced by liver metabolites.
Fukuda, H; Ikenaga, M; Matsunaga, N; Nakanishi, T; Tamai, I, 2012
)
0.38
"In this study, capillary electrophoresis (CE) combined with HPLC-MS/MS were used as a powerful platform for screening of inhibitors of mammalian target of rapamycin (mTOR) in natural product extracts."( Screening of mammalian target of rapamycin inhibitors in natural product extracts by capillary electrophoresis in combination with high performance liquid chromatography-tandem mass spectrometry.
Kang, J; Li, F; Li, M; Zhang, Y, 2015
)
0.42
" Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to various types of drugs, and understanding how these drugs interact is of the utmost importance."( Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.
Andersson, BS; Hassan, M; Valdez, BC, 2017
)
0.46
"This study aimed at investigating the clinical effect of ranibizumab combined with panretinal photocoagulation in the treatment of macular edema in diabetic retinopathy (DR) patients."( Optical Coherence Tomography Combined with Fluorescein Fundus Angiography under Intelligent Algorithm to Evaluate the Clinical Efficacy of Ranibizumab Combined with Panretinal Photocoagulation in the Treatment of Macular Edema of Diabetic Retinopathy Pati
Huang, J; Li, L; Zhou, Q, 2022
)
0.72
" Clinically significant drug interactions can be induced by organic anion transporter 1 (OAT1) and OAT3 when concomitant medications competitively interact with the transporters."( Sensitive and valid assay for reliable evaluation of drug interactions mediated by human organic anion transporter 1 and 3 using 5-carboxyfluorescein.
Chae, YJ; Chang, JE; Lee, KR, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The use of absorbable intracanalicular collagen implants may increase the bioavailability of topically applied ocular solutions."( Effect of intracanalicular collagen implants on the absorption of topically applied sodium fluorescein.
Hill, JH; Kaufman, HE; Reidy, JJ; Unterman, SR, 1991
)
0.28
" Blood concentration-time profiles could not be adequately described by models involving a simple first-order absorption process; a model incorporating two simultaneous first-order inputs gave a much better description, its absorption rate constants differing by almost two orders of magnitude."( Pulmonary absorption of carboxyfluorescein in the rat.
Kellaway, IW; Smith, A; Taylor, G; Woolfrey, SG, 1986
)
0.27
" The results obtained here, together with our previously reported data, indicate that the interference between sodium salicylate and drug self-association behavior, by increasing drug solubility, may substantially contribute to the improved drug bioavailability mediated by salicylate."( Prevention of molecular self-association by sodium salicylate: effect on insulin and 6-carboxyfluorescein.
Alhaique, F; Fisher, P; Memoli, A; Riccieri, FM; Santucci, E; Touitou, E, 1987
)
0.27
" Bioavailability of fluorescein by oral administration was 99%."( Studies on the pharmacokinetics of fluorescein and its dilaurate ester under the conditions of the fluorescein dilaurate test.
Barry, RE; Behrendt, WA, 1985
)
0.27
" Formulation of Calcein (a water-soluble marker molecule, MW = 623), or SK&F 106760 (a water-soluble RGD peptide, MW = 634) in a w/o microemulsion having a composition of Captex 355/Capmul MCM/Tween 80/Aqueous (65/22/10/3, % w/w), resulted in significant bioavailability enhancement in rats relative to their aqueous formulations."( Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides.
Constantinides, PP; Ellens, H; Lancaster, C; Marcello, J; Marks, G; Scalart, JP; Smith, PL, 1994
)
0.29
" The absorption enhancing activity of w/o microemulsions incorporating these lipids was evaluated in the rat using Calcein (MW = 623) a water-soluble and poorly absorbed marker molecule."( Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation.
Constantinides, PP; Ellens, H; Owen, AB; Smith, PL; Sturgis, S; Welzel, G; Yiv, SH, 1996
)
0.29
" The large amount of calcein leakage induced by enhancers was consistent with an enhancement of bioavailability of verapamil and insulin following nasal administration (oleic acid < SG < Sit-G)."( The enhancing effect of soybean-derived sterylglucoside and beta-sitosterol beta-D-glucoside on nasal absorption in rabbits.
Kamata, K; Maitani, Y; Nagai, T; Nakamura, K; Suenaga, H; Takayama, K, 2000
)
0.31
" The aim of this study was to assess the systemic bioavailability of this rationally designed drug in 16 patients with advanced solid cancers."( Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.
Brown, G; Carmichael, J; Clayton, KT; Eatock, MM; McLelland, HR; Moyses, C; O'Byrne, KJ; Sharma, RA; Steward, WP; Twelves, CJ, 2001
)
0.31
"Linear pharmacokinetics and oral bioavailability of approximately 25% were observed at the dose levels used in this study."( Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.
Brown, G; Carmichael, J; Clayton, KT; Eatock, MM; McLelland, HR; Moyses, C; O'Byrne, KJ; Sharma, RA; Steward, WP; Twelves, CJ, 2001
)
0.31
"The systemic bioavailability and half-life of oral OGT 719 are sufficient to merit dose escalation studies with frequent daily dosing."( Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.
Brown, G; Carmichael, J; Clayton, KT; Eatock, MM; McLelland, HR; Moyses, C; O'Byrne, KJ; Sharma, RA; Steward, WP; Twelves, CJ, 2001
)
0.31
" This article describes the application of flow cytometry to the development of bioassays with marine and freshwater algae for assessing the bioavailability of contaminants in waters and sediments."( Applications of flow cytometry to ecotoxicity testing using microalgae.
Adams, MS; Franklin, NM; Stauber, JL, 2002
)
0.31
" This clinical observation stimulated our interest to investigate the differences of drug bioavailability in upper and lower fornixes in three different head positions."( Differences in bioavailability of fornixes in different head positions.
Hsu, SY; Lin, CP, 2002
)
0.31
" Bioavailability and cellular uptake of (-)-epicatechin are not yet fully characterized."( Amphiphilic properties of (-)-epicatechin and their significance for protection of cells against peroxynitrite.
Klotz, LO; Schroeder, P; Sies, H, 2003
)
0.32
" However, it cannot be excluded that co-administration of Pgp inhibitors such as ritonavir or paroxetine could increase MDMA, MDE and PMA bioavailability and also enhance brain entry leading to severe side effects."( P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
Haefeli, WE; Ketabi-Kiyanvash, N; Mikus, G; Weiss, J, 2003
)
0.32
" Hence, infection and inflammatory diseases may impose variability in drug bioavailability through alterations in the intestinal expression and activity of drug transporters and metabolic enzymes."( Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
Brocks, DR; Kalitsky-Szirtes, J; Piquette-Miller, M; Shayeganpour, A, 2004
)
0.32
" Therefore, these findings indicated that the viscous vehicles were effective to regulate the absorption rate of CF."( Control of pulmonary absorption of water-soluble compounds by various viscous vehicles.
Fujita, T; Muramatsu, H; Muranishi, S; Nishinaka, A; Okada, N; Okumura, S; Yamada, K; Yamamoto, A, 2004
)
0.32
" The in vivo delivery of CF by electroporation in mice demonstrated the potential of HPCD for sustaining the transdermal absorption rate of hydrophilic molecules."( Cyclodextrin enhanced transdermal delivery of piroxicam and carboxyfluorescein by electroporation.
Hui, SW; Murthy, SN; Sen, A; Zhao, YL, 2004
)
0.32
" Modulation of intestinal Pgp dependent transport by GFJ may lead to changes in bioavailability of drugs that are substrates of Pgp itself, by affecting their presystemic clearance."( Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2.
Chieli, E; Donati, A; Romiti, N; Tramonti, G, 2004
)
0.32
" These findings could form the basis for the development of electroporation as a clinical tool to increase intestinal permeability and, thereby, increase the absorption of poorly absorbed drugs."( Increased permeability of intestinal epithelial monolayers mediated by electroporation.
Ghartey-Tagoe, EB; Morgan, JS; Neish, AS; Prausnitz, MR, 2005
)
0.33
"Multidrug resistance-associated protein 2 (MRP2) is associated with active drug efflux and may influence oral bioavailability of common classes of drugs."( Antibiotic exposure does not influence MRP2 functional expression in Caco-2 cells.
Hirst, BH; Moore, V; Prime-Chapman, H, 2005
)
0.33
"Oral administration of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) has been reported to increase the bioavailability of various macromolecules."( Investigation of the enhancing mechanism of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate effect on the intestinal permeability of polar molecules utilizing a voltage clamp method.
Hess, S; Hoffman, A; Rotshild, V, 2005
)
0.33
"Phenolic acids such as p-coumaric acid and microbial metabolites of poorly absorbed polyphenols are absorbed by the monocarboxylic acid transporter (MCT)-mediated transport system which is identical to the fluorescein/H(+) cotransport system."( Non-involvement of the human monocarboxylic acid transporter 1 (MCT1) in the transport of phenolic acid.
Konishi, Y; Tohjo, Y; Watanabe, H; Yashiro, T, 2006
)
0.33
"Stratum corneum composition and structure limit cutaneous bioavailability of pharmaceutical and cosmetical agents."( In vitro evaluation of the effect of electrotreatment on skin permeability.
Kalia, YN; Levy, JL; Marra, F; Santi, P, 2008
)
0.35
" In continuation of the tests investigating the factors limiting bioavailability of boswellic acids, the present study examined the permeability of KBA and AKBA in human Caco-2 cell lines."( Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2.
Abdel-Tawab, M; Fricker, G; Hummel, J; Kanzer, J; Krüger, P; Schubert-Zsilavecz, M, 2009
)
0.35
" Comparison of exposure to the intravenous and subcutaneous doses indicated 100% bioavailability following subcutaneous administration."( Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Anastassov, V; Bodart, V; Bridger, GJ; Darkes, MC; Fricker, SP; Idzan, SR; Labrecque, J; Lau, G; Macfarland, RT; Mosi, RM; Neff, KS; Nelson, KL; Patel, K; Ruzek, MC; Santucci, Z; Scarborough, R; Wong, RS, 2009
)
0.35
" Intestinal cells constitute a first barrier to mycotoxins exposure, since they express membrane ABC transporters that may affect the bioavailability of food xenobiotics."( ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites.
Delaforge, M; Lecoeur, S; Mazallon, M; Prouillac, C; Videmann, B, 2009
)
0.35
" Analyses of the absorption-enhancing effects of w/o/w emulsions on intestinal calcein absorption in rats showed that calcein bioavailability after intraduodenal (i."( Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound.
Koga, K; Takada, K; Takarada, N, 2010
)
0.36
" These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2."( Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010
)
0.36
"Food contains components that may either increase or decrease the bioavailability of a drug."( Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G.
Fukami, T; Furuishi, T; Hidaka, S; Nakatsuma, A; Suzuki, T; Tomono, K, 2010
)
0.36
" This study thus demonstrates for the first time that the proteolytic activation and thus bioavailability of BMP2 is controlled by PC6."( Posttranslational activation of bone morphogenetic protein 2 is mediated by proprotein convertase 6 during decidualization for pregnancy establishment.
Hardman, B; Heng, S; Li, Y; Nie, G; Paule, S; Rainczuk, A; Singh, H; Stephens, AN, 2010
)
0.36
" However, their high hydrophilicity results in a poor bioavailability hindering the development of efficient antioxidant strategies."( Does hydrophobicity always enhance antioxidant drugs? A cut-off effect of the chain length of functionalized chlorogenate esters on ROS-overexpressing fibroblasts.
Cabello, G; Chabi, B; Laguerre, M; Lecomte, J; López Giraldo, LJ; Villeneuve, P; Wrutniak-Cabello, C, 2011
)
0.37
"Red blood cells (RBC) play an important role in the balance between generation and scavenging of nitric oxide (NO) and hence its local bioavailability and influence on vasomotor control."( Shear stress activation of nitric oxide synthase and increased nitric oxide levels in human red blood cells.
Baskurt, OK; Celik-Ozenci, C; Johnson, PC; Meiselman, HJ; Ulker, P; Yalcin, O; Yaras, N, 2011
)
0.37
" This substrate specificity of gemifloxacin towards these efflux transporters may be one of the major factors accounting for low oral bioavailability (71%)."( Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.
Kwatra, D; Mitra, AK; Pal, D; Vadlapatla, RK; Vadlapudi, AD, 2011
)
0.37
" However, GRed EA was not elevated indicating that reduced glutathione (GSH) is not comparably recovered as consumed, leading to a decreased bioavailability of GSH and increased oxidative stress."( Reduced antioxidant capacities in platelets from patients with autoimmune thrombocytopenia purpura (ITP).
Arbach, O; Bal, G; Kamhieh-Milz, J; Kamhieh-Milz, S; Salama, A; Sterzer, V, 2012
)
0.38
"In the recent years a significant development of investigations with regard to bioavailability of ocular drugs has been noticed."( Bovine corneal epithelial primary cultures as an in vitro model for ophthalmic drugs studies.
Paluch, M; Sieradzki, E; Sitkiewicz, D; Stawarski, T; Sygitowicz, G; Zapolska-Downar, D,
)
0.13
" Hence, infection and inflammatory diseases may induce variability in drug bioavailability through alterations in the intestinal expression and activity of drug transporters."( Suppression of efflux transporters in the intestines of endotoxin-treated rats.
Hatanaka, M; Hayashi, M; Kai, T; Kanbayashi, A; Murata, H; Nakaike, M; Takizawa, Y; Tanaka, A; Tomita, M, 2012
)
0.38
" In Mdr1a knockout rats, loperamide and paclitaxel oral bioavailability was 2- and 4-fold increased, respectively, whereas clearance was significantly reduced (40-42%), consistent with the expected 10- to 20-fold reduction in paclitaxel excretion."( Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Bao, JQ; Bedwell, DW; Higgins, JW; Zamek-Gliszczynski, MJ, 2012
)
0.38
" Fluorescence of 3-amino-4-(N-methylamino)-2',7'-difluorofluorescein (DAF-FM) and dihydroethidium (DHE) were used for quantification of nitric oxide bioavailability and superoxide concentration, respectively."( Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate.
Lai, EY; Liu, ZZ; Patzak, A; Perlewitz, A; Persson, PB; Sendeski, MM; Viegas, VU, 2012
)
0.38
" Decreased nitric oxide bioavailability and increased concentration of superoxide explain the increased tone and reactivity in afferent arterioles perfused with iodixanol."( Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration rate.
Lai, EY; Liu, ZZ; Patzak, A; Perlewitz, A; Persson, PB; Sendeski, MM; Viegas, VU, 2012
)
0.38
" The stronger in vivo effect of (+)-catechin on L-DOPA methylation compared to the other dietary compounds is due to its better bioavailability in vivo."( Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Fukui, M; Kang, KS; Wen, Y; Yamabe, N; Zhu, BT, 2013
)
0.39
" Bioavailability in plasma was done by chromatographic analysis."( Therapeutic potential of treatment with the flavonoid rutin after cortical focal ischemia in rats.
Frazão Muzitano, M; Giraldi-Guimarães, A; Marcilio, Fdos S; Rodrigues, AM, 2013
)
0.39
" However, these methods do not quantify chemokine bioavailability and bioactivity, variables modified by many environmental factors including composition of the extracellular matrix (ECM)."( Visualizing chemokine-dependent T cell activation and migration in response to central nervous system infection.
Carson, MJ; Wilson, EH, 2013
)
0.39
"The overall goal of this paper was to enhance the bioavailability of orally delivered insulin."( In vitro cell culture evaluation and in vivo efficacy of amphiphilic chitosan for oral insulin delivery.
Sharma, CP; Shelma, R, 2013
)
0.39
" The bioavailability and efficacy of antioxidants in human corneal limbal epithelial (HCLE) cells were measured to determine whether antioxidants might be beneficial constituents of lubricant eye drops."( Bioavailability of antioxidants applied to stratified human corneal epithelial cells.
Koetje, LR; Mitchell, AK; Schotanus, MP; Stoddard, AR; Ubels, JL, 2013
)
0.39
" These results demonstrate that heat enhances vascular carrying capacity and bioavailability of large molecules around growth plates, suggesting that temperature could be a noninvasive strategy for modulating delivery of therapeutics to impaired growth plates of children."( Hindlimb heating increases vascular access of large molecules to murine tibial growth plates measured by in vivo multiphoton imaging.
Efaw, ML; Serrat, MA; Williams, RM, 2014
)
0.4
" A waveguide exposure system with 1 W input power provided the mean specific absorption rate of ≈0."( Effects of 940 MHz EMF on bioluminescence and oxidative response of stable luciferase producing HEK cells.
Faraji-Dana, R; Foolad, F; Hosseinkhani, S; Khodagholi, F; Moosavi-Movahedi, AA; Sefidbakht, Y; Torkzadeh-Mahani, M, 2014
)
0.4
"The membrane protein P-glycoprotein (P-gp) plays key roles in the oral bioavailability of drugs, their blood brain barrier passage as well as in multidrug resistance."( Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors.
Dittrich, PS; Eyer, K; Herger, M; Krämer, SD, 2014
)
0.4
" DFO antioxidant and iron binding properties were preserved and its bioavailability was increased upon CPP conjugation, which opens new therapeutic possibilities for neurodegenerative processes associated with brain iron overload."( Cell penetrating peptide (CPP)-conjugated desferrioxamine for enhanced neuroprotection: synthesis and in vitro evaluation.
Esposito, BP; Goswami, D; Machini, MT; Nomura, CS; Silvestre, DM, 2014
)
0.4
" Nevertheless, the limited systemic bioavailability of phytochemicals may raise questions regarding the physiological relevance of their phytochemical effects in vivo."( Oxidant-based anticancer activity of a novel synthetic analogue of capsaicin, capsaicin epoxide.
Chochrek, P; Lewinska, A; Rawska, E; Smolag, K; Wnuk, M, 2015
)
0.42
" In addition, the influence of NCB on the bioavailability of chamaechromone following their co-administration was also determined in rats."( Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
Bi, H; Hu, H; Huang, M; Lou, Y; Pan, L; Wang, X; Zeng, K; Zeng, S, 2015
)
0.42
" These findings indicate that SLG-30 is an effective absorption-enhancer for improving the intestinal absorption of poorly absorbed drugs, without causing serious damage to the intestinal epithelium."( Absorption-enhancing effects of gemini surfactant on the intestinal absorption of poorly absorbed hydrophilic drugs including peptide and protein drugs in rats.
Alama, T; Katsumi, H; Kusamori, K; Sakane, T; Yamamoto, A, 2016
)
0.43
" Unfortunately, due to the low bioavailability and consequently low blood level, they cannot be used for cancer therapy."( Anthocyanidins but not anthocyanins inhibit P-glycoprotein-mediated calcein extrusion - possible implication for orally administered drugs.
Vrzal, R, 2016
)
0.43
"The simultaneous processes of lipid digestion and absorption together determine the oral bioavailability of drugs incorporated into lipid based drug delivery systems (LBDDS)."( Simultaneous lipolysis/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems.
Bauer-Brandl, A; Bibi, HA; Holm, R, 2017
)
0.46
" Thus, altered functionality of ABCB1 and ABCC2 can affect the disposition and bioavailability of administered drugs, interfering with AED therapy."( In Vitro Assessment of the Effect of Antiepileptic Drugs on Expression and Function of ABC Transporters and Their Interactions with ABCC2.
Grewal, GK; Kanojia, N; Kukal, S; Kukreti, R; Madan, K; Saso, L, 2017
)
0.46
" It can confer broad-spectrum multidrug resistance and can decrease the bioavailability of many important drugs."( Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
Iram, SH; Peterson, BG; Sampson, A; Tan, KW, 2019
)
0.51
" The free zinc concentration, which describes the fraction of zinc that is only loosely bound and easily exchangeable, has been proposed for this purpose, as it reflects the highly bioavailable part of serum zinc."( A Zinpyr-1-based Fluorimetric Microassay for Free Zinc in Human Serum.
Alker, W; Haase, H; Schomburg, L; Schwerdtle, T, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In the DSS group, there was a delay in the elimination phase, suggesting a decrease in renal function, and an increase in maximum blood concentration, associated with an increased absorption rate constant."( Increased membrane permeation and blood concentration of 6-carboxyfluorescein associated with dysfunction of paracellular route barrier in the small intestine of ulcerative colitis model rats.
Ishii, M; Kumagai, M; Morimoto, K; Tomita, M, 2020
)
0.56
" Even though many food additives are poorly absorbed into systemic circulation, high concentrations could exist in the intestinal lumen, making intestinal drug transporters, such as the uptake transporter organic anion transporting polypeptide 2B1 (OATP2B1), a possible site of food additive-drug interactions."( Food Additives as Inhibitors of Intestinal Drug Transporter OATP2B1.
Deng, F; Hagström, M; Kidron, H; Koenderink, JB; Pierrot, E; Sánchez, VB; Tikkanen, A, 2020
)
0.56
" This device can provide a simple, noninvasive, extended drug release up to 45 days with higher bioavailability and lower risk for adverse effects."( Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment.
Ben-Shlomo, G; Ding, X; Que, L, 2020
)
0.56
"Capryol 90 is an effective absorption enhancer for improving the intestinal absorption of poorly absorbed drugs via both transcellular and paracellular pathways."( Absorption-Enhancing Mechanisms of Capryol 90, a Novel Absorption Enhancer, for Improving the Intestinal Absorption of Poorly Absorbed Drugs: Contributions to Trans- or Para-Cellular Pathways.
Imanishi, A; Kaneda, A; Katsumi, H; Kimura, E; Koyama, M; Morishita, M; Ukai, H; Yamamoto, A, 2020
)
0.56
" First of all, we verified that P80 promoted the bioavailability of MEHP-AF in the long-term and low-dose exposure of MEHP-AF with P80 as a result of increasing the intestinal absorption of MEHP-AF."( Food emulsifier polysorbate 80 promotes the intestinal absorption of mono-2-ethylhexyl phthalate by disturbing intestinal barrier.
Feng, QP; Hu, MY; Li, WJ; Wu, X; Xiang, SY; Yu, SQ; Yuan, YZ; Zhu, YT, 2021
)
0.62
"P-glycoprotein (P-gp) over-expression plays a vital role in not only systemic drug bioavailability but also cancer multi-drug resistance (MDR)."( A novel flavonoid from Fissistigma cupreonitens, 5‑hydroxy‑7,8‑dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance.
Hung, CC; Lan, YH; Lin, KI; Lin, YC; Teng, YN; Thang, TD, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" In oral dosing experiments, volumes calculated at least 50, 200 or 1000 times the human daily use level were administered."( Subacute administration of Plak-Lite sodium fluorescein solution in hamsters.
Schwartzman, RM; Yankell, SL, 1977
)
0.26
"105 patients were orally given fluorescein of different dosage and concentration for fundus angiography."( [The effect of dosage on oral fluorescein angiography of the fundus].
Li, RX; Zhang, SL, 1992
)
0.28
" Fundus fluorescence under slitlamp illumination was poor for patients receiving the lower dosage of fluorescein, whereas at the higher dosage it was visible in all but one patient."( Oral fluorescein angiography and fluoroscopy: determination of plasma fluorescein levels and clinical application.
Gómez-Ulla, F; Malvar, A; Parafita, M; Polo, P; Seoane, I, 1992
)
0.28
" The dose-response to three agents--ethanol, doxorubicin, and sodium hypochlorite--is shown and, in the case of sodium hypochlorite, compared to in vivo skin toxicity with a high correlation."( Skin toxicity determined in vitro by three-dimensional, native-state histoculture.
Hoffman, RM; Li, LN; Margolis, LB, 1991
)
0.28
"The motility of bile canaliculi was examined in hepatocyte couplets permeabilized with palmitoyl lysophosphatidyl choline in a dosage regimen that drastically affected secretory function, yet maintained relative integrity of the cellular cytoskeleton."( Permeabilized hepatocyte couplets. Adenosine triphosphate-dependent bile canalicular contractions and a circumferential pericanalicular microfilament belt demonstrated.
Edwards, V; Phillips, MJ; Smith, CR; Tsukada, N; Watanabe, N, 1991
)
0.28
" The permeability of the pulmonary barrier was assessed by the rate of transfer of disodium fluorescein dosed as 100 microliters of aqueous solution (1 mg/ml) after administering the surfactants."( Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein.
Byron, PR; Niven, RW, 1990
)
0.28
" In the third study, the corneal permeability to fluorescein was determined in 10 subjects after dosing with 50 ppm H2O2, 500 ppm H2O2, as well as negative and positive controls."( Clinical aspects of topical application of dilute hydrogen peroxide solutions.
McNally, JJ,
)
0.13
" Dosage and frequency of application should be as limited as possible."( [Poisoning by disinfectants in the conservative treatment of 2 patients with omphalocele].
Monnens, LA; Schröder, CH; Severijnen, RS, 1985
)
0.27
" In dose-response curves the extent of the cytoskeletal association appears to follow the extent of bridging, continuing to increase beyond where stimulated degranulation is maximal."( Cross-linking of immunoglobulin E-receptor complexes induces their interaction with the cytoskeleton of rat basophilic leukemia cells.
Baird, B; Holowka, D; Robertson, D, 1986
)
0.27
" A direct dose-response relationship was found between BK concentration and clearance of FITC-Dextran 150."( Quantitation of bradykinin-induced microvascular leakage of FITC-dextran in rat cremaster muscle.
Borić, MP; Durán, WN; Roblero, JS, 1987
)
0.27
" In this study, we quantitated the dose-response effects of topically applied PAF on microvascular permselectivity and investigated the biochemical pathways of this compound."( Effect of platelet-activating factor on microvascular permselectivity: dose-response relations and pathways of action in the hamster cheek pouch microcirculation.
Dillon, PK; Durán, WN, 1988
)
0.27
" High voltage stimulation (HVS) was applied simultaneously with the histamine to the vascular bed of the treatment animals in a dosage of 10, 30, or 50 V; the control animals received no electrical stimulation."( Effect of high voltage pulsed electrical stimulation on microvascular permeability to plasma proteins. A possible mechanism in minimizing edema.
Reed, BV, 1988
)
0.27
"97) was observed between the dose of administered goat 125I-IgG and the amount bound to isolated glomeruli over the entire dosage range."( Quantitation of antigen in tissue by immunofluorescence image analysis.
Basgen, JM; Michael, AF; Nevins, TE, 1989
)
0.28
" The diacylglycerols OAG and diC8 produced biphasic dose-response curves leading to rounding up of cells at very high stimulant concentrations."( Diacylglycerols and PMA induce actin polymerization and distinct shape changes in lymphocytes: relation to fluid pinocytosis and locomotion.
Keller, HU; Niggli, V; Zimmermann, A, 1989
)
0.28
" A dose-response ouabain (1 mM) sensitive relationship exists between [Na+]o and retardation of the reversal phenomenon."( Induced interphase cell retraction: its reversal and EGF potentiation.
Sit, KH; Wong, KP, 1989
)
0.28
" Based on a comparison of dose-response curves for inhibition of fluoresceinated fMet-Leu-Phe-Lys binding, the relative affinity of the peptide for the receptor was comparable to that of fMet-Leu-Phe-Lys."( Staphylococcus aureus tetrapeptide with high chemotactic potency and efficacy for human leukocytes.
Henderson, LE; Leonard, EJ; Rot, A; Sowder, R, 1989
)
0.28
" dosing (18 min)."( Pulmonary absorption of carboxyfluorescein in the rat.
Kellaway, IW; Smith, A; Taylor, G; Woolfrey, SG, 1986
)
0.27
" Applying this new method to HIV-infected MT-4 cell cultures treated with differing concentrations of the potent anti-HIV agent azidothymidine (AZT), we obtained a virus-inhibitory dose-response comparable to those obtained by the conventional (labour-intensive and time-consuming) methods."( A highly reliable, sensitive, flow cytometric/fluorometric assay for the evaluation of the anti-HIV activity of antiviral compounds in MT-4 cells.
Balzarini, J; De Clercq, E; Pauwels, R; Schols, D; Vanlangendonck, F, 1988
)
0.27
" This toxic effect was dependent upon dosage of erythrosin B administered, time of light exposure and, to a much lesser extent, the length of time the larvae were left in culture in the presence of the dye."( Photodynamic action of erythrosin B as a toxic mechanism for infective larvae of bovine gastrointestinal nematodes.
Hawkins, JA; Heitz, JR; Johnson-Delivorias, MH, 1986
)
0.27
" Evaluations of coded video recordings revealed a smooth dose-response relationship and validated a semiquantitative method of analysis."( Vital microscopy of islet blood flow: catecholamine effects in normal and ob/ob mice.
Rooth, P; Täljedal, IB, 1987
)
0.27
" The analysis of two unusual time profiles implied that the regional distribution of solid and dissolved material, between perfused areas and nonperfused areas, could be nonhomogeneous despite the use of a standardized dosing technique."( Solute absorption from the airways of the isolated rat lung. I. The use of absorption data to quantify drug dissolution or release in the respiratory tract.
Byron, PR; Niven, RW, 1988
)
0.27
" The process of permeabilization proceeds as a pseudo first-order reaction, indicating that the toxin is active as a monomer; consistently no evidence for cooperativity has been found in a dose-response titration."( Escherichia coli hemolysin permeabilizes small unilamellar vesicles loaded with calcein by a single-hit mechanism.
Menestrina, G, 1988
)
0.27
" FCM quantification of E-BSA-FITC binding intensity demonstrates a saturable dose-response that is specifically reduced in the presence of diethylstilbestrol (DES) in doses known to saturate Type I ER."( Flow cytometric analysis of fluorescein-conjugated estradiol (E-BSA-FITC) binding in breast cancer suspensions.
Benz, C; Lee, SH; Wiznitzer, I, 1985
)
0.27
"Fluorescein-labelled sulodexide tissue distribution was studied in the rat after intravenous administration at the dosage of 15 mg/kg."( Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: Organ distribution in rats.
Franchi, M; Guizzardi, S; Mastacchi, R; Morocutti, M; Ruggeri, A, 1985
)
0.27
" The dosage and the amount of liquid to be drunk by adults were reduced."( [Diagnosis of pancreatic insufficiency using fluorescein-dilaurate in children (author's transl)].
Neis, P; Zeuss, F, 1981
)
0.26
" The time-dependent increase of TAA after administration of 100 mg/kg acetylsalicylic acid is demonstrated; the dosage finally delayed TAA to longer than 360 seconds."( Platelet aggregation induced in the hamster cheek pouch by a photochemical process with excited fluorescein isothiocyanate-dextran.
Herrmann, KS, 1983
)
0.27
" The addition of factors from the supernatants of concanavalin A-stimulated rat spleen cell cultures was necessary to obtain linear dose-response curves and strong primary responses."( The analysis of an anti-fluorescein cytotoxic response.
Christensen, N; Marbrook, J; Skinner, M, 1983
)
0.27
" The dose-response curves for parameters were powers with negative exponent indicating considerable saturation of the F-GAG elimination process."( Pharmacokinetics of fluorescein-labelled glycosaminoglycans and of their lipoprotein lipase-inducing activity in the rat.
Madonna, M; Pescador, R, 1982
)
0.26
" Immediately afterwards a lethal dosage of anesthetic was given and the maxilla, including the VNO, was removed, frozen, and cut into transverse sections."( Flehmen and vomeronasal organ function in male goats.
Hart, BL; Ladewig, J, 1980
)
0.26
" In addition, quantitative dosage screening can discriminate female carriers."( Duchenne/Becker muscular dystrophy carrier detection using quantitative PCR and fluorescence-based strategies.
Fortina, P; Lebo, RV; Lucero, MY; Mansfield, ES; Mayrand, PE; Parrella, T; Rappaport, E; Robertson, JM; Sartore, M; Surrey, S, 1993
)
0.29
"A peroral dosage form was examined to deliver recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the colon in beagle dogs."( Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs.
Ikeda, C; Imagawa, N; Niwa, K; Takada, K; Takaya, T, 1995
)
0.29
" Like all GPIIb/IIIa antagonists, DMP 728 has a steep dose-response relationship in inhibiting platelet aggregation."( Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide.
Bozarth, JM; Flint, SK; Forsythe, MS; Jackson, SA; Mousa, SA; Tsao, PW, 1995
)
0.29
"01), with a dose-response relationship for increases in Wb."( The response of rat tibiae to incremental bouts of mechanical loading: a quantum concept for bone formation.
Forwood, MR; Turner, CH,
)
0.13
" This dosage schedule will maintain a relatively constant level of corticosteroid action throughout a 24-hour period."( The effect of oral dexamethasone on the circadian rhythm of aqueous humor flow in humans.
Brubaker, RF; Larsson, LI; Rettig, ES; Sheridan, PT; Young, WF, 1994
)
0.29
" Our results suggest that adaptation of physiological mechanisms governing the exocrine pancreas may occur after one week of receptor blockade by a therapeutic dosage of telenzepine, to the extent that M1-blockade no longer inhibits secretion."( Exocrine pancreatic secretion in man following one week of M1-muscarinic receptor blockade.
Ditschuneit, H; Glasbrenner, B; Kemmer, TP; Malfertheiner, P; Nelson, DK; Schneider, A, 1993
)
0.29
" MPTP produced a slight but significant decrease of DA only 4 hours post dosing on PND 23."( Age-related susceptibility to MPTP-induced neurotoxicity in mice.
Ali, SF; David, SN; Newport, GD, 1993
)
0.29
" The routine assay for characterizing a specific photosensitizer at a standard dose consists of the sequential allocation of eight mice to a set of different light doses designed to span the dose-response range of fluorescein fluorescence exclusion (measured 8-10 min after fluorescein injection)."( The validation of a new vascular damage assay for photodynamic therapy agents.
Bellnier, DA; Greco, WR; Henderson, BW; Johnson, P; Parsons, JC; Potter, WR; Sitnik, TM; Vaughan, LA; Whitaker, J, 1995
)
0.29
" The present study determined the time course and the dose-response relationship of radiation-induced hyperpermeability in cultured bovine pulmonary artery endothelial (BPAE) cells."( Dose-response effects of radiation on the permeability of endothelial cells in culture.
Molteni, A; Taylor, JM; Ward, WF; Waters, CM, 1996
)
0.29
" A dose-response of AFB1 was also observed within the range of 10 nM to 1000 nM."( Detection of elevated reactive oxygen species level in cultured rat hepatocytes treated with aflatoxin B1.
Ong, CN; Shen, HM; Shen, Y; Shi, CY, 1996
)
0.29
" The dose-response curve of IL-1 alpha-induced uveitis was inhibited in a non-competitive manner."( Tetrandrine inhibits breakdown of blood-aqueous barrier induced by endotoxin and interleukin-1 alpha in rats.
Chiou, GC; Xiao, JG, 1996
)
0.29
" Quantitative dose-response values obtained from surviving cell fractions assayed by flow cytometry at 24 h following drug exposure demonstrated the utility of this assay for quantitating drug-induced cytotoxic effects on primary human AML cells in short-term culture."( Quantitative measurements of the efficacy of new anti-cancer agents on fresh human AML cells by using multivariate flow analysis.
Edelstein, MB; KuKuruga, MA; Media, JE; Nakeff, A; Valeriote, F, 1996
)
0.29
" At high phospholipid concentrations, the leakage of CF from PC LUVs deviates from a simple dose-response relationship, and it appears that some of the squalamine can no longer cause leakage."( The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles.
Dollahon, NR; Fojtik, KG; Jones, SR; Selinsky, BS; Shinnar, AE; Zhou, Z, 1998
)
0.3
" A dose-response curve was generated for norepinephrine in concentrations of 100 nM-100 microM."( Effect of norepinephrine on proliferation, migration, and adhesion of SV-40 transformed human corneal epithelial cells.
Araki-Sasaki, K; Campbell, S; Marfurt, CF; Murphy, CJ, 1998
)
0.3
"Delivery of drugs through the skin and the buccal mucosa has been considered as an alternative to per oral dosing for those substances that are degraded in the gastro-intestinal tract, or are subject to first-pass metabolism in the liver."( Buccal mucosa in vitro experiments. I. Confocal imaging of vital staining and MTT assays for the determination of tissue viability.
Cullander, C; Imbert, D, 1999
)
0.3
"Our aim was to compare and evaluate apoptosis formation as detected by propidium-iodide (PI)/annexin-V or PI/fluorescein-diacetate (FDA) as dose-response parameters in a human promyelocytic leukemia cell line, HL60."( Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate.
Bartkowiak, D; Baust, H; Högner, S; Nothdurft, W; Röttinger, EM, 1999
)
0.3
" In these cells at low dosage (from 1 to 6 microg/ml of medium) ET-18-OCH(3) stimulates maturation and protective responses, whereas at increasing dosages (from 8 to 20 microg/ml) it shows cytotoxic effects."( ET-18-OCH(3)-induced cytotoxicity and DNA damage in rat astrocytes.
Cardile, V; Palumbo, M; Renis, M; Russo, A, 2000
)
0.31
" Multiple factors such as dose of light, means of application, wavelength, irradiation area, total dose of the dye, and multiple dosing may be altered in the future to improve the antifibrotic effect of photodynamic therapy during surgery for glaucoma."( Photodynamic therapy to control fibrosis in human glaucomatous eyes after trabeculectomy: a clinical pilot study.
Diestelhorst, M; Grisanti, S, 2002
)
0.31
" Moreover, the FP measurements can be used for the diagnosis, and making timing and dosage decisions."( The induction of apoptosis by methotrexate in activated lymphocytes as indicated by fluorescence hyperpolarization: a possible model for predicting methotrexate therapy for rheumatoid arthritis patients.
Deutsch, M; Ehrenfeld, M; Herman, S; Langevitz, P; Zurgil, N, 2003
)
0.32
" From dose-response curves with Sf9 membrane vesicles, glutathionylcurcumin conjugates appeared to be less potent inhibitors of MRP1 and MRP2 than their parent compound curcumin."( Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Boersma, MG; Cnubben, NH; Rietjens, IM; Spenkelink, B; Usta, M; van Bladeren, PJ; van der Velde, AE; van Zanden, JJ; Wortelboer, HM, 2003
)
0.32
" Results were measured with a fluorescent multiwell plate reader and dose-response curves were obtained successfully with both procedures."( Comparing a ciliate and a fish cell line for their sensitivity to several classes of toxicants by the novel application of multiwell filter plates to Tetrahymena.
Bols, NC; Dayeh, VR; DeWitte-Orr, SJ; Grominsky, S; Lee, LE; Lynn, DH; Sotornik, D; Yeung, CR,
)
0.13
"5 cGy with linear dose-response curves."( Standardization of a fluorometric assay for measuring oxidative stress in irradiated cells.
Kennedy, AR; Wan, XS; Ware, JH; Zhou, Z, 2005
)
0.33
" The animals were treated with either one of the drugs at previously defined relevant dosage or control."( Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine.
Gahm, C; Holmin, S; Mathiesen, T; Rudehill, S, 2005
)
0.33
" Dose-response curves were generated using various NO donors and reactive nitrogen and oxygen species."( The novel red-fluorescent probe DAR-4M measures reactive nitrogen species rather than NO.
Busija, DW; Csordás, A; Horváth, EM; Kollai, M; Lacza, Z; Pankotai, E; Szabó, C,
)
0.13
" These data demonstrated that full Runx2 gene dosage is required for maintaining normal function of osteoblasts in mechanical unloading or nonphysiological condition."( Runx2 is a target of mechanical unloading to alter osteoblastic activity and bone formation in vivo.
Ezura, Y; Komori, T; Nakashima, K; Noda, M; Salingcarnboriboon, R; Tsuji, K, 2006
)
0.33
" The dosage form was evaluated for physicochemical, adherence, and in vitro diffusion parameters."( Bioadhesive tablets for controlled transdermal delivery of drugs.
Bharath, S; Murthy, SN; Vishwanath, BA,
)
0.13
" The concentrations of stilbenes decreasing BCPCF transport by 50% during 60 min of incubation at 37 degrees C (IC50) were determined from dose-response curves."( Resveratrol oligomers are potent MRP1 transport inhibitors.
Bobrowska-Hägerstrand, M; Hägerstrand, H; Lillås, M; Motohashi, N; Mrówczyñska, L; Shirataki, Y; Wróbel, A,
)
0.13
"The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis."( Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006
)
0.33
" Parenteral depots including biodegradable polymer microspheres offer the possibility of reduced dosing frequency but are limited by the inability to adequately control delivery rates."( Macromolecule release from monodisperse PLG microspheres: control of release rates and investigation of release mechanism.
Berkland, C; Kim, K'; Pack, DW; Pollauf, E; Raman, C; Silverman, R, 2007
)
0.34
" In a separate study, brain damage 3 days after stroke was determined histologically in mice receiving no treatment, DMSO, or NGP1-01 (dosages and dosage schedule same as above)."( Neuroprotection in mice by NGP1-01 after transient focal brain ischemia.
Abbruscato, TJ; Bickel, U; Geldenhuys, WJ; Hao, J; Klein, J; Mdzinarishvili, A; Van der Schyf, CJ, 2008
)
0.35
" The purpose of this investigation was to quantify the dose-response aspect of Purkinje cell loss and rapid cellular degradation indicative of Purkinje cell loss following a single alcohol exposure on postnatal day 5 in lobule I, a lobule that has been shown to be vulnerable to alcohol-induced injury during cerebellar development."( Alcohol exposure on postnatal day 5 induces Purkinje cell loss and evidence of Purkinje cell degradation in lobule I of rat cerebellum.
Eskue, K; Lee, Y; Maier, SE; Rowe, J; West, JR, 2008
)
0.35
" The inhibitory potency of the tested drugs from the dose-response relationships was cyclosporin A>verapamil> phenytoin> carbamazepine> lamotrigine>phenobarbital>valproic acid, levetiracetam, gabapentin."( Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs.
Chen, CC; Hung, CC; Lin, CJ; Liou, HH, 2008
)
0.35
" The reduction in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups."( HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats.
Gurkoff, GG; Kozikowski, AP; Lyeth, BG; Van, KC; West, EJ; Zhang, B; Zhang, XM; Zhou, J, 2008
)
0.35
" A dose-response study suggested that quercetin showed protective effects against Abeta(1-42) toxicity by modulating oxidative stress at lower doses, but higher doses were not only non-neuroprotective but also toxic."( Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease.
Abdul, HM; Ansari, MA; Butterfield, DA; Joshi, G; Opii, WO, 2009
)
0.35
"5h following subcutaneous dosing in mice and with maximum peak plasma concentration of compound preceding peak mobilization in dogs, indicating that AMD3465 has the potential to mobilize hematopoietic stem cells."( Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Anastassov, V; Bodart, V; Bridger, GJ; Darkes, MC; Fricker, SP; Idzan, SR; Labrecque, J; Lau, G; Macfarland, RT; Mosi, RM; Neff, KS; Nelson, KL; Patel, K; Ruzek, MC; Santucci, Z; Scarborough, R; Wong, RS, 2009
)
0.35
"More accurate dose-response curves can be constructed by eliminating aqueous serial dilution of compounds."( Gradient, contact-free volume transfers minimize compound loss in dose-response experiments.
Datwani, S; Ellson, R; Harris, D; Olechno, J, 2010
)
0.36
" Once confirmed by dose-response assays (EC(50)=26 microM), we verified V-ATPase inhibition by disulfiram in secondary assays that measured ATP hydrolysis in vacuolar membranes."( Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by high-throughput screening flow cytometry.
Allen, C; Johnson, RM; Melman, SD; Parra, KJ; Sklar, LA; Waller, A; Young, SM, 2010
)
0.36
" These effects were all reversed by co-treatment with pyruvate at a well-tolerated dosage (1000 mg/kg)."( Protective effect of pyruvate against ethanol-induced apoptotic neurodegeneration in the developing rat brain.
Kim, MO; Koh, PO; Lee, HY; Naseer, MI; Ullah, I; Ullah, N, 2011
)
0.37
" Etoposide was administered at a dosage of 30 or 60 mg/kg."( Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: a mechanistic study.
Attia, SM, 2012
)
0.38
" The physicochemical and pharmacokinetic properties of NOSC-modified DTX liposomes (NDLs) were evaluated compared with the conventional DTX liposomes (DLs) and commercial dosage form of DTX, Taxotere(®)."( N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: preparation, characterization, and pharmacokinetics.
Qu, G; Wu, X; Yin, L; Zhang, C, 2012
)
0.38
" We show that real-time flow cytometric quantification of compound-uptake is reliably measured and that analyzing their respective uptake kinetic provides additional valuable information which can be used for improving drug dosage and delivery."( Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics.
Efferth, T; Eichhorn, T; Korn, B; Paulsen, M; Wiench, B, 2012
)
0.38
"In 51 adult patients undergoing living donor liver transplantation (OLT), immunosuppressive drugs were dosed on the basis of immune monitoring by the MLR assay (optimized protocol: group O)."( Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients.
Ide, K; Ishiyama, K; Ohdan, H; Onoe, T; Tanaka, Y; Tashiro, H, 2012
)
0.38
" These results may provide a possible explanation for higher methadone dosage requirements in patients carrying variant-type of P-gp and revealed the possible drug-drug interactions in patients who receive concomitant drugs which are also P-gp substrates."( Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone.
Chiou, MH; Hsieh, YW; Huang, CL; Hung, CC; Lane, HY; Teng, YN, 2013
)
0.39
" In this context, our main aim in this research was to establish a dose-response curve of Acylpeptide hydrolase (APH) and AChE regional brain activity after acute CPF administration that could explain these long term effects observed in the literature."( Dose-dependent regional brain acetylcholinesterase and acylpeptide hydrolase inhibition without cell death after chlorpyrifos administration.
Cañadas, F; Cardona, D; Flores, P; Llorens, J; López-Granero, C; Pancetti, F; Sánchez-Santed, F, 2013
)
0.39
" In some dosage conditions of methyl-β-cyclodextrin, the membrane permeability of 5-CF was significantly increased in the jejunum, but such change was not observed in the ileum."( Effects of pharmaceutical excipients on membrane permeability in rat small intestine.
Furuya, T; Hayashi, M; Kishimoto, H; Nakagawa, M; Sakamoto, N; Takizawa, Y; Tobe, Y; Tomita, M, 2013
)
0.39
" In recent years, photo-responsive nanoparticles (NPs) have received considerable attention because of their potentials in providing spatial, temporal, and dosage control over the drug release."( Non-invasive controlled release from gold nanoparticle integrated photo-responsive liposomes through pulse laser induced microbubble cavitation.
Gao, Y; Liu, Q; Liu, Y; Mathiyazhakan, M; Ohl, CD; Tam, KC; Xu, C; Yang, Y; Zhu, C, 2015
)
0.42
"25 g L(-1) dosage increased from 8 to 68 %, the percentage of intact cells decreased from 94."( Effects of Fructus ligustri lucidi on the growth, cell integrity, and metabolic activity of the Microcystis aeruginosa.
Ge, H; Wu, Y; Zhou, Z, 2015
)
0.42
" A dose-response curve was generated for itraconazole and clarithromycin (maximal concentration 100 μM) and compared to that of Zosuquidar, a highly specific known P-gp inhibitor."( Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells.
Bleier, BS; Han, X; Hoang, JD; Lam, A; Singleton, A, 2015
)
0.42
"Both itraconazole and clarithromycin demonstrated a dose-response curve for P-gp inhibition similar to that of Zosuquidar."( Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells.
Bleier, BS; Han, X; Hoang, JD; Lam, A; Singleton, A, 2015
)
0.42
" Following the primary screen at 80μM, dose-response curves were used to investigate in detail 86 compounds, identifying 16 low μM inhibitors and providing data about the structure-activity relationships in four series containing 19, 24, 10, and eight analogues."( Exploring the structure-activity relationships of ABCC2 modulators using a screening approach.
Finel, M; Ghemtio, L; Kidron, H; Kudryavtsev, P; Tammela, P; Urtti, A; Wipf, P; Wissel, G; Xhaard, H; Yliperttula, M, 2015
)
0.42
" The PK were derived noncompartmentally using all data points up to 6 hours after dosing or only using the concentrations at 10 and 30 minutes after injection."( Effects of renal insufficiency on the elimination of fluorescein lisicol (NRL972), an investigational marker of hepatic transporter function.
de Mey, C; Deliyska, B; Gatchev, E, 2015
)
0.42
" The plasma concentrations of NRL972 declined rapidly after dosing in mostly monoexponential fashion."( Effects of renal insufficiency on the elimination of fluorescein lisicol (NRL972), an investigational marker of hepatic transporter function.
de Mey, C; Deliyska, B; Gatchev, E, 2015
)
0.42
" After dosed for 24 h and 72 h, the NO release of low dose groups were higher than those of the controls, while the NO release of high dose groups showed a downward trend when compared with the control's."( [Effects of atrazine on function of murine peritoneal macrophages in vitro].
Chen, J; Ma, S; Zhang, L, 2015
)
0.42
"Photo-responsive nanoparticles (NPs) have received considerable attention because of their potential in providing spatial, temporal, and dosage control over the drug release."( Synthesis of Gold Nanoparticle Integrated Photo-responsive Liposomes and Measurement of Their Microbubble Cavitation upon Pulse Laser Excitation.
Chan, W; Mathiyazhakan, M; Ohl, CD; Xu, C, 2016
)
0.43
" After five days culture, the hepatocytes were incubated with a dosing solution including CDF or Rhodamine 123."( Novel multiple assessment of hepatocellular drug disposition in a single packaged procedure.
Ichikawa, H; Kanda, K; Takahashi, R, 2016
)
0.43
"Transdermal administration of drugs represents an excellent alternative to conventional pharmaceutical dosage forms."( A Novel Chemical Enhancer Approach for Transdermal Drug Delivery with C
Hijikuro, I; Kadhum, WR; Sekiguchi, S; Sugibayashi, K; Todo, H, 2017
)
0.46
" CPD-4645 (10 mg/kg, subcutaneously) or vehicle was dosed 1 and 7 h after status epilepticus onset in video-electroencephalography (EEG) recorded mice."( Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet.
Butler, CR; Guilmette, E; Pauletti, A; Piro, JR; Porcu, L; Rizzi, M; Salamone, A; Samad, TA; Sheehan, MJ; Terrone, G; Vezzani, A; Villa, BR, 2018
)
0.48
" CDFDA dosing models were based on simultaneous fitting of CDF levels in apical, basolateral, and intracellular compartments."( Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells.
Drennen, C; Gorse, E; Stratford, RE, 2018
)
0.48
" In conclusion, these results may assist, in a mechanism-based, selection of suitable surfactants for formulating oral dosage forms to enhance the absorption of low bioavailable P-gp substrates."( Nonionic surfactants increase digoxin absorption in Caco-2 and MDCKII MDR1 cells: Impact on P-glycoprotein inhibition, barrier function, and repeated cellular exposure.
Al-Ali, AAA; Holm, R; Nielsen, CU; Steffansen, B, 2018
)
0.48
" With the emergence of living therapeutics, engineered microbes can deliver and produce increasingly complex medicine, and controlling the mucoadhesive properties of different microbial chassis can dictate dose-response in a patient."( Quantifying and Engineering Mucus Adhesion of Probiotics.
Chappell, TC; Mays, ZJS; Nair, NU, 2020
)
0.56
" However, both modi require a very accurate real-time dosing control in order to avoid extended retinal disintegration in this power range."( Investigations on Retinal Pigment Epithelial Damage at Laser Irradiation in the Lower Microsecond Time Regime.
Birngruber, R; Brinkmann, R; Grisanti, S; Kleingarn, P; Miura, Y; Seifert, E; Sonntag, SR; Theisen-Kunde, D, 2021
)
0.62
" This specialized assessment may require dosing neonatal rats at postnatal day 7 at the peak of the brain growth spurt and evaluating brain tissue 24 to 48 hours following dosing."( Use of Both Fluoro-Jade B and Hematoxylin and Eosin to Detect Cell Death in the Juvenile Rat Brain Exposed to NMDA-Receptor Antagonists or GABA-Receptor Agonists in Safety Assessment.
Davis, S; Mendes, OR; Picut, CA; Swanson, C; Weil, DS, 2021
)
0.62
" This toxic effect was dependent upon dosage of erythrosin B administered, time of light exposure and, to a much lesser extent, the length of time the larvae were left in culture in the presence of the dye."( Photodynamic action of erythrosin B as a toxic mechanism for infective larvae of bovine gastrointestinal nematodes.
Hawkins, JA; Heitz, JR; Johnson-Delivorias, MH, 1986
)
0.27
" In short-term mechanistic studies in rats there was a log-dose response relationship in circulating levels of thyroid and pituitary hormones plus a similar non-linear dose-response in morphologic changes in thyroid follicular cells."( Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system.
Capen, CC, 1998
)
0.3
" Under the batch studies, effect of concentration of dye, temperature, pH of the solution, dosage of adsorbents, sieve size of adsorbents, etc."( Process development for the removal and recovery of hazardous dye erythrosine from wastewater by waste materials-Bottom Ash and De-Oiled Soya as adsorbents.
Kurup, L; Mittal, A; Mittal, J; Singh, AK, 2006
)
0.33
" The effects of pH, concentration of the dye, temperature, and adsorbent dosage have been studied."( Adsorption of a hazardous dye, erythrosine, over hen feathers.
Gupta, VK; Kurup, L; Mittal, A; Mittal, J, 2006
)
0.33
" Then the dependency of dyes removal percentage in their ternary solution on the level and magnitude of variables such as sonication time, initial dyes concentrations and adsorbent dosage was fully investigated and optimized by central composite design (CCD) under response surface methodology (RSM) as well as by regarding desirability function (DF) as a good and general criterion."( Simultaneous ultrasound-assisted ternary adsorption of dyes onto copper-doped zinc sulfide nanoparticles loaded on activated carbon: optimization by response surface methodology.
Asfaram, A; Bazrafshan, AA; Ghaedi, M; Goudarzi, A; Hajati, S, 2015
)
0.42
" The developed methods were applied to estimate rupatadine content in its pharmaceutical tablet dosage form with acceptable recoveries."( Resonance Rayleigh scattering and spectrofluorimetric approaches for the selective determination of rupatadine using erythrosin B as a probe: application to content uniformity test.
Abdel-Lateef, MA; Almahri, A; Derayea, SM; El Hamd, MA; Samir, E, 2021
)
0.62
" The approaches were successful in determining nilotinib in a pharmaceutical dosage form as well as spiked human plasma samples."( Utility of a xanthene-based dye for determination of nilotinib using two spectroscopic approaches. Applications to bulk powder, capsules, and spiked human plasma.
Dagher, D; El-Enany, N; Elmansi, H; Nasr, JJ, 2023
)
0.91
" This approach was utilized for measuring sunitinib in its dosage forms and spiked plasma."( Utility of the food colorant erythrosine B as an effective green probe for quantitation of the anticancer sunitinib. Application to pharmaceutical formulations and human plasma.
AboShabana, R; Belal, F; El Sharkasy, ME; Tolba, MM; Walash, MI, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (30 Items)

ItemProcessFrequency
Snackscore-ingredient16
Confectioneriescore-ingredient14
Sweet snackscore-ingredient14
Candiescore-ingredient11
Candy canescore-ingredient3
Condimentscore-ingredient3
Chewing gumcore-ingredient2
sucréscore-ingredient2
Groceriescore-ingredient2
Saucescore-ingredient2
Meal replacementscore-ingredient1
Chewing gum with sugarcore-ingredient1
Gummi candiescore-ingredient1
Spicescore-ingredient1
Plant-based foodscore-ingredient1
Plant-based foods and beveragescore-ingredient1
Jelly beanscore-ingredient1
Bonbons gélifiéscore-ingredient1
Bonbonscore-ingredient1
Confiseriescore-ingredient1
Couronnes des roiscore-ingredient1
Briochescore-ingredient1
Viennoiseriescore-ingredient1
Surgeléscore-ingredient1
Custard powdercore-ingredient1
Custards and pastry creamscore-ingredient1
Pastry helperscore-ingredient1
Dessert saucescore-ingredient1
Cooking helperscore-ingredient1
Dairiescore-ingredient1

Protein Targets (74)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency29.15120.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.50120.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency37.61880.044717.8581100.0000AID485294; AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency28.18380.125919.1169125.8920AID2549
LuciferasePhotinus pyralis (common eastern firefly)Potency23.63110.007215.758889.3584AID1224835; AID588342; AID624030
acetylcholinesteraseHomo sapiens (human)Potency42.41070.002541.796015,848.9004AID1347395; AID1347397; AID1347398
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency31.62283.981127.764939.8107AID504842
phosphopantetheinyl transferaseBacillus subtilisPotency14.12540.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.06950.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency31.25740.173734.304761.8120AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency12.99000.004110.890331.5287AID504466
Fumarate hydrataseHomo sapiens (human)Potency15.84890.00308.794948.0869AID1347053
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624170
SMAD family member 3Homo sapiens (human)Potency31.25740.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency21.13600.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency6.47270.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency10.58260.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
thioredoxin glutathione reductaseSchistosoma mansoniPotency0.89130.100022.9075100.0000AID485364
hypothetical protein, conservedTrypanosoma bruceiPotency35.48130.223911.245135.4813AID624173
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency43.64860.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.76750.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency9.58900.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.92060.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency12.44380.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.87340.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency19.49710.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency17.37680.00108.379861.1304AID1645840
polyproteinZika virusPotency15.84890.00308.794948.0869AID1347053
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency10.00000.707936.904389.1251AID504333
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency11.13600.023723.228263.5986AID743222; AID743241
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.58490.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency15.63790.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency24.05040.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.63420.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259393; AID1259395
activating transcription factor 6Homo sapiens (human)Potency13.96220.143427.612159.8106AID1159516
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency17.40980.154917.870243.6557AID1346891
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency13.63190.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency53.88060.039147.5451146.8240AID1224845; AID1224896
Bloom syndrome protein isoform 1Homo sapiens (human)Potency22.38720.540617.639296.1227AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency4.46680.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency26.96800.010039.53711,122.0200AID1469; AID1479
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency19.90090.000323.4451159.6830AID743065; AID743067
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency11.22020.65619.452025.1189AID463254
eyes absent homolog 2 isoform aHomo sapiens (human)Potency12.58931.199814.641950.1187AID488837
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency3.16230.075215.225339.8107AID485360
DNA polymerase kappa isoform 1Homo sapiens (human)Potency26.67950.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency6.68970.251215.843239.8107AID504327
relaxin receptor 1 isoform 1Homo sapiens (human)Potency158.48900.038814.350143.6206AID2676
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency19.55120.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency24.58520.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency27.61680.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency19.55120.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency23.93410.060110.745337.9330AID485367
LuciferasePhotinus pyralis (common eastern firefly)Potency48.84760.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency76.49640.002541.796015,848.9004AID1347395; AID1347397
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency41.24703.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.63640.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency16.31700.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency10.34020.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency9.80850.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency4.90980.000214.376460.0339AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency33.50290.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency26.70340.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency15.51600.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.39610.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.55440.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.52750.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.93130.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency22.15540.023723.228263.5986AID743222; AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency27.36160.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency23.88690.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259393; AID1259395
activating transcription factor 6Homo sapiens (human)Potency40.22030.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency26.77310.154917.870243.6557AID1346891
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency29.764319.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency29.76430.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency34.07050.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency36.21420.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency29.81850.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency70.76540.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency15.15260.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency42.82050.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency15.15260.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Zika virusIC50 (µMol)1.70001.10001.94004.1000AID1659175
large T antigenBetapolyomavirus macacaeIC50 (µMol)13.04000.160024.9724100.0000AID1903
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)2.90000.17004.559010.0000AID1594139
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)2.90000.17004.559010.0000AID1594139
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)9.20000.06003.96319.7000AID1594135
60 kDa chaperonin Escherichia coliIC50 (µMol)0.85000.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)0.85000.03903.55529.8000AID1594140; AID1594141
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Zika virusEC50 (µMol)0.60000.02200.30730.6000AID1659178
Flavin reductase (NADPH)Homo sapiens (human)Kd0.15920.07000.79681.7100AID1815675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (207)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
megakaryocyte differentiationFlavin reductase (NADPH)Homo sapiens (human)
heme catabolic processFlavin reductase (NADPH)Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayFlavin reductase (NADPH)Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (76)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
biliverdin reductase (NAD(P)H) activityFlavin reductase (NADPH)Homo sapiens (human)
protein bindingFlavin reductase (NADPH)Homo sapiens (human)
FMN reductase (NAD(P)H) activityFlavin reductase (NADPH)Homo sapiens (human)
peptidyl-cysteine S-nitrosylase activityFlavin reductase (NADPH)Homo sapiens (human)
riboflavin reductase (NADPH) activityFlavin reductase (NADPH)Homo sapiens (human)
FMN reductase (NADPH) activityFlavin reductase (NADPH)Homo sapiens (human)
FMN reductase (NADH) activityFlavin reductase (NADPH)Homo sapiens (human)
biliberdin reductase NAD+ activityFlavin reductase (NADPH)Homo sapiens (human)
biliverdin reductase (NADPH) activityFlavin reductase (NADPH)Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmFlavin reductase (NADPH)Homo sapiens (human)
nucleoplasmFlavin reductase (NADPH)Homo sapiens (human)
cytosolFlavin reductase (NADPH)Homo sapiens (human)
plasma membraneFlavin reductase (NADPH)Homo sapiens (human)
intracellular membrane-bounded organelleFlavin reductase (NADPH)Homo sapiens (human)
extracellular exosomeFlavin reductase (NADPH)Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1815673Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in entropy by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID1815675Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID1465889Ratio of IC50 for human Fc-conjugated CD40/FLAG-tagged biotinylated CD40L costimulatory protein-protein interaction in presence of Triton-X 100 to IC50 for human Fc-conjugated CD40/FLAG-tagged biotinylated CD40L costimulatory protein-protein interaction i2017Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21
Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction.
AID1815674Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in gibbs free energy by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID1659178Inhibition of Zika virus NS2B-NS3 protease by cell based assay2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Inhibitors of the Zika virus protease NS2B-NS3.
AID1659175Inhibition of Zika virus NS2B-NS3 protease2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Inhibitors of the Zika virus protease NS2B-NS3.
AID1815672Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in enthalpy by isothermal titration calorimetry2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15,221)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905890 (38.70)18.7374
1990's3249 (21.35)18.2507
2000's3074 (20.20)29.6817
2010's2574 (16.91)24.3611
2020's434 (2.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.40 (24.57)
Research Supply Index9.65 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index127.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials108 (0.70%)5.53%
Trials25 (4.96%)5.53%
Reviews218 (1.41%)6.00%
Reviews8 (1.59%)6.00%
Case Studies181 (1.17%)4.05%
Case Studies4 (0.79%)4.05%
Observational7 (0.05%)0.25%
Observational0 (0.00%)0.25%
Other14,969 (96.68%)84.16%
Other467 (92.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]